Diagonal Bio chooses OIM Sweden
Diagonal Bio AB and OIM Sweden have signed an agreement regarding the further development of Diagonal’s product Panviral.
Diagonal Bio AB was founded in 2020 and is a Swedish biotech company with its registered office in Lund, Sweden. The company is developing the Panviral platform to detect and diagnose small sections of pathogens through, for example, viruses, bacteria, and fungi. The company was founded with the goal of reducing human suffering by using proprietary technology to revolutionize global diagnostics of pathogen-borne diseases.
Diagonal is currently focusing on optimizing and improving the performance of Panviral. As part of the improvement work, Diagonal has signed a cooperation agreement with the Malmö-based company OIM Sweden AB. The agreement relates to a framework agreement for the further development of Panviral. OIM Sweden AB is one of Sweden’s most innovative product development companies, with a concept that combines technical competence with people, innovation, and business acumen. OIM Sweden AB develops products for successful companies through its innovative approach to product development.
“- The agreement is in line with Diagonal’s strategic plans. The local presence has been a central part of the decision as OIM Sweden AB is a Malmö-based company, which promotes and enables close cooperation. The close collaboration gives Diagonal the opportunity to follow all aspects of the development and ensure that the company anchors essential knowledge and know-how internally in the company”, says Jack Egelund Madsen, CEO of Diagonal Bio.
“- We are extremely proud and happy that Diagonal Bio chooses OIM Sweden as its product development partner. With OIM’s experience in MedTech and with an ISO 13485 certification, we look forward to continuing to develop Panviral together with Diagonal. The new business collaboration with Diagonal consolidates our position in Medtech and creates the opportunity to in partnership really make a difference for people and the world we live in. We look forward with great confidence to the collaboration that affects technology, people, and innovation on several levels”, says Ann Kryhl, CEO of OIM Sweden AB.
Contact:
Jack Egelund Madsen, VD, Diagonal Bio AB
Telefon: +46 73 526 27 59
E-post: jem@diagonalbio.com
Ann Kryhl, VD, OIM Sweden AB
Telefon: 0733-20 00 67
E-post: ann.kryhl@oimsweden.com
Sofie Magnoy, Marknadschef
Telefon: 0766-26 15 16
E-post: sofie.magnoy@oimsweden.com